- 2006-2010: NHMRC Principal Research Fellow, QIMR.
- 2001-2005: NHMRC Senior Research Fellow, QIMR.
- 1997-2000: NHMRC R. Douglas Wright Fellow, QIMR.
- 1996: Senior Research Officer, QIMR.
- 1995-1996: Research Officer, QIMR.
- 1993-1994: UQ Postdoctoral Fellow, The University of Queensland.
- 1990-1993: Research Officer, QIMR.
Current Area of Research
The primary focus of our research group has been human immune regulation. The major goals of our laboratory are to obtain a deeper understanding of the mechanisms by which the human immune response to viral infections and human cancers may be generated, augmented and applied to the treatment of these diseases.
We have used Epstein-Barr virus-associated diseases as a model to understand how cellular immune response in humans responds to persistent viral infections. Over the last 15 years, we have successfully translated our laboratory research towards the development of novel immunotherapeutic strategies for the treatment of virus-associated cancers.
Our group has successfully completed multiple clinical trials and is currently involved in three new clinical trials which involves adoptive transfer of autologous virus-specific T cells in patients with different clinical indications (e.g. nasopharyngeal carcinoma, glioblastoma and post-transplant infectious complications). We also have a highly successful research program to develop T cell based therapeutic and prophylactic strategies for human cytomegalovirus (CMV)-associated diseases.
- Successfully completed ‘first in man’ Phase I clinical trials on adoptive immunotherapy for recurrent glioblastoma (GBM) and nasopharyngeal carcinoma (NPC).
- Initiated a Phase I clinical trial on adoptive immunotherapy for drug-resistant CMV infection in solid organ transplant patients (funded by NHMRC).
- Developed a novel T cell therapy for progressive multiple sclerosis (Phase I clinical trial to start May/June 2015).
- Initiated two new Phase I/II clinical trials to assess therapeutic efficacy of combination therapy for metastatic NPC and primary GBM.
- Awarded international patents which have been licensed to national and international pharma/biotech companies.
- Commercial launch of a QuantiFERON-CMV immune monitoring kit developed with our IP.
- Major advance in CMV vaccine program with funding through NHMRC Development grant.
- Attracted more than $8.15 m in research funding from various national and international funding agencies in last five years.
- In Nov 2014, selected as Queensland’s top 50 ‘Best and Brightest’.
- Elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
- Australasian Society for Immunology (Queensland State Councillor 1995 to 1997).
- International Epstein-Barr virus Association.
- American Society of Haematology (ASH).
- American Association for Immunologist (AAI).
- American Association for Microbiology (ASM).
- European Society for Cancer Immunology and Immunotherapy (ESCII).
- Jenner Society.
- 2015: Elected as a Fellow of the Australian Academy of Health and Medical Sciences (AAHMS).
- 1995: Beckman Postdoctoral Prize (QIMR).
- 1993-1994: The University of Queensland Post-Doctoral Research fellowship.
- 1987-1989: Open Research Fellowship from Indian Council of Medical Research (ICMR), New Delhi, India.
- Certificate of Merit from Panjab University, India.
- 1984: University Student Council Medal for academic performance.
- 1984: University Medal for academic performance during postgraduate studies.
- 1990: PhD Postgraduate Institute of Medical Education and Research, India.
- 1984: MSc Panjab University, India.
- 1982: BSc (Medical) Panjab University, India.